Oral S2-Ag85 DNA Vaccine Activated Intestinal Cell dsDNA and RNA Sensors to Promote the Presentation of Intestinal Antigen

Figure 2

The S2-Ag85A vaccine promotes antibody secretion from IEC and DC cells to reduce the production of proinflammatory factors. ELISA to detect (a) IFN-β expression in IEC and DC cells, with significantly increased IFN-β expression in DC cells of the S2-Ag85A group (); (b) IFN-γ expression in IEC and DC cells, with significantly increased IFN-γ expression in DC cells of the S2-Ag85A group (); (c) IL-1β expression in IEC and DC cells, with significantly increased IL-1β expression in the S2-Ag85A group (); (d) IL-1β expression in IEC and DC cells, with significantly lower expression of IL-1β in the S2-Ag85A and S2 groups than the control group; (e) MIP-1α expression in IEC cells, with significantly increased expression in the S2-Ag85A group (); (f) ICA-M1 expression in IEC cells, with significantly lower expression in both the S2-Ag85A and S2 groups than in the control group (); (g) TLR4 expression in DC cells. (h) CXCL10 expression in DC cells. RT-PCR for (i) IFN-α (), IL-6, TGF-β, MCP-1, and TECK and (j) CD11, CD86, MCHII (), CCL5, CD80, and IL-6 in IEC cells.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)